News - Markets & Marketing, Vertex


Current filters:

Markets & MarketingVertex

Popular Filters

Incivek and Victrelis important advances in HCV, but still unmet needs


Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market


One year post launch, Vertex's (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co (NYSE: MRK) and Roche's…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek versus Victrelis in hepatitis C virus treatment: US physician views


For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Hepatitis C drug market in Mexico expected to double to $104 million in 2015


The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Vertex’ Incivek set to break record for fastest product launch


Vertex Pharmaceuticals’ (Nasdaq: VRTX) new hepatitis C drug Incivek (telaprevir) is being touted…

FinancialIncivekMarkets & MarketingPharmaceuticalVertex

Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice


Three months after the launch of Vertex’ Incivek (telaprevir) and Merck & Co/Roche’s Victrelis…

IncivekMarkets & MarketingMerck & CoPharmaceuticalRocheVertexVictrelis

Launch trends for Incivek and Victrelis in hepatitis C sector


Results from a survey fielded one month after the launch of Vertex’ (Nasdaq: VRTX) Incivek (telaprevir)…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Back to top